# Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

> **NCT03972189** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 111 (estimated)

## Conditions studied

- ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** TQ-B3101

## Key facts

- **NCT ID:** NCT03972189
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-24
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2019-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972189, "Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03972189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*